Keyphrases
12-month Mortality
11%
Adverse Events
33%
Adverse Health
33%
Anticoagulant Therapy
42%
Anticoagulants
8%
Anticoagulation
18%
Autoimmune Disease
33%
Bleeding
11%
Bleeding Events
11%
Cancer Patients
16%
Cancer Treatment
8%
Confidence Interval
11%
COVID-19
33%
Deep Vein Thrombosis
25%
Developed Countries
33%
Differentiated Approach
8%
Emblica
33%
Enfermedad
33%
Epistaxis
11%
HAART Era
33%
HAART Initiation
11%
Hazard Ratio
11%
Healthcare
33%
Hemostasis
8%
Hereditary Hemorrhagic Telangiectasia
33%
Highly Active Antiretroviral Therapy (HAART)
22%
HIV Patients
33%
Hospital Stay
11%
Human Immunodeficiency Virus Type 1 (HIV-1)
11%
In Cancer
8%
In Care
11%
Incidental
8%
Infected Patients
33%
International Society
8%
Late Presentation
11%
Major Bleeding
20%
Natural History
33%
Non-majors
16%
Oncologists
8%
Patient Characterization
33%
Patients with Cancer
33%
Pneumocystis Jirovecii
33%
Pulmonary Embolism
16%
Recurrent Venous Thromboembolism
27%
RIETE Registry
41%
Splanchnic Vein Thrombosis
8%
Superficial Vein Thrombosis
33%
Tertiary Hospital
33%
Thrombosis
8%
Venous Thromboembolism
100%
Medicine and Dentistry
Anticoagulant Therapy
40%
Anticoagulation
14%
Antithrombotic
8%
Autoimmune Disease
33%
Blood Stasis
8%
Cancer Therapy
8%
Deep Vein Thrombosis
56%
Epistaxis
7%
Hazard Ratio
11%
Hereditary Hemorrhagic Telangiectasia
33%
Highly Active Antiretroviral Therapy
33%
Human Immunodeficiency Virus
33%
Low Molecular Weight Heparin
5%
Lower Limb
33%
Major Bleeding
23%
Malignant Neoplasm
20%
Oncologist
8%
Phlebothrombosis
8%
Pneumocystis Jirovecii
33%
Pneumocystis Pneumonia
18%
Pulmonary Embolism
18%
Recurrent Disease
28%
Superficial Thrombophlebitis
33%
Thrombosis
8%
Venous Thromboembolism
100%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Drug Reaction
6%
Adverse Event
33%
Anticoagulant Agent
10%
Autoimmune Disease
33%
Bleeding
20%
Case Fatality Rate
6%
Comorbidity
6%
Deep Vein Thrombosis
48%
Disease
6%
Epistaxis
7%
Infection
6%
Low Molecular Weight Heparin
5%
Lung Embolism
22%
Malignant Neoplasm
33%
Observational Study
6%
Phyllanthus
33%
Recurrent Disease
28%
Rendu Osler Weber Disease
33%
SARS Coronavirus
33%
Vein Superficial Thrombosis
33%
Venous Thromboembolism
66%
